Related Experiment Video

Updated: Jun 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease

Xiang Li1, Cheng Liu, Jian Cui

  • 1Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Basic & Clinical Pharmacology & Toxicology
|January 16, 2009
PubMed

Insights

Activated dendritic cells in coronary heart disease patients were inhibited by pravastatin, reducing inflammation independently of cholesterol levels. This suggests a role for dendritic cells in heart disease pathogenesis and pravastatin

Area of Science:

  • Immunology
  • Cardiology
  • Pharmacology

Background:

  • Dendritic cells (DCs) play a crucial role in immune responses.
  • Immune dysregulation is implicated in the pathogenesis of coronary heart disease (CHD).
  • The functional profile of DCs in CHD and the impact of statins require further elucidation.

Purpose of the Study:

  • To investigate the functional characteristics of dendritic cells in patients with coronary heart disease (CHD).
  • To evaluate the effects of pravastatin on dendritic cell function and associated inflammatory markers in CHD patients.
  • To explore the relationship between dendritic cell activation, inflammation, and lipid profiles in CHD.

Main Methods:

  • Peripheral blood dendritic cells (DCs) were isolated from CHD patients and healthy controls.
  • DC surface marker expression (CD86), immunostimulatory capacity (mixed lymphocyte reaction), and cytokine profiles were assessed.
  • Effects of pravastatin (10 mg/day and 20 mg/day) were evaluated, alongside measurements of blood lipids and high-sensitivity C-reactive protein (hs-CRP).

Main Results:

  • Patients with CHD exhibited increased CD86 expression and enhanced immunostimulatory capacity of DCs compared to healthy individuals.
  • CHD patients showed elevated pro-inflammatory and reduced anti-inflammatory cytokine secretion by T lymphocytes.
  • Pravastatin treatment significantly inhibited DC function and reduced hs-CRP levels, independent of plasma cholesterol reduction. No significant dose-dependent difference was observed.

Conclusions:

  • Dendritic cell activation is evident in coronary heart disease, suggesting a role in its pathogenesis.
  • Pravastatin effectively inhibits dendritic cell activation and reduces inflammation in CHD patients.
  • The anti-inflammatory effects of pravastatin in this context are independent of its cholesterol-lowering properties.

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...